New combo pill aims to extend life in tough bile duct cancer

NCT ID NCT06622057

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding an experimental drug (D07001) to standard chemotherapy (capecitabine) helps people with advanced bile duct cancer live longer. About 195 adults whose cancer has not responded to earlier treatments will receive either D07001 or a placebo, plus capecitabine. The goal is to see if the combination improves overall survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER (BTC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms carcinoma of the ampulla of vater cholangiocarcinoma gallbladder cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    NOT_YET_RECRUITING

    Kaohsiung City, 807, Taiwan

    Contact

    Contact Phone: •••-•••-••••

  • University Hospital Cleveland Medical Center

    RECRUITING

    Cleveland, Ohio, 44106, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••